Author： Naldi L.
Publisher： Informa Healthcare
ISSN： 1354-3784
Source： Expert Opinion on Investigational Drugs, Vol.6, Iss.7, 1997-07, pp. : 895-898
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Psoriasis is a chronic disabling skin disorder which is the end result of a pathological process involving genetic and environmental elements. Both a T-cell origin and a primary defect in keratinocytes have been considered as the starting point. Recently, transgenic animal models and severe combined immunodeficiency (SCID) grafting have been developed. Research into the basic biology and immunology of psoriasis is generating a wide range of new treatments, including differentiating agents and immunomodulatory drugs. Flaws in conducting clinical trials of psoriasis have been repeatedly described, and methodological improvements are required.
Related content
Access to resources
Recommend
Developing Novel Therapeutic Approaches to Frailty
Current Pharmaceutical Design, Vol. 15, Iss. 29, 2009-10 ,pp. :
Novel Therapeutic Approaches to Mitochondrial Disease
Letters in Drug Design & Discovery, Vol. 1, Iss. 4, 2004-10 ,pp. :